Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis/Nestle deal closes

This article was originally published in The Tan Sheet

Executive Summary

Nestle completed its acquisition of Novartis Medical Nutrition July 1 following "the successful conclusion of the regulatory process," Nestle announces. The Novartis unit and its roughly 2,000 employees will be integrated into Nestle Nutrition, Nestle says. "The acquisition propels Nestle into a strong number two position globally in the fast-growing and lucrative healthcare nutrition market, helping to accelerate the profitable development of the overall nutrition business," the firm adds. Plans for the transaction were announced in December (1"The Tan Sheet" Dec. 18, 2006, p. 8)...

You may also be interested in...

Nestle Looks To Cook Up Nutrition Product Sales With Novartis MN Acquisition

Nestle looks to become the number two company in the healthcare nutrition field, including the infant formula market, with its planned $2.5 bil. acquisition of Novartis' Medical Nutrition unit

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts